Skip to main content
Erschienen in: Annals of Hematology 9/2013

01.09.2013 | Original Article

The effect of diabetes mellitus and end-stage renal disease on the number of CD34+ cells in the blood

verfasst von: Cigdem Pala, Ilker Altun, Yavuz Koker, Fatih Kurnaz, Serdar Sivgin, Ismail Koçyiğit, Fatih Tanrıverdi, Leylagul Kaynar, Ferhan Elmali, Mustafa Cetin, Bülent Eser

Erschienen in: Annals of Hematology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the effect of end-stage renal disease (ESRD) and diabetes mellitus (DM) on the number of stem cells in the peripheral blood. Sixty-two patients diagnosed with ESRD who had not received dialysis previously, 25 patients with a diagnosis of DM without nephropathy, and 21 healthy volunteers were included in the study. The group diagnosed with ESRD was divided into two groups. The first group (DM-CRD) consisted of 28 patients with DM who had developed chronic renal disease (CRD). The second group (NON-DM-CRD) consisted of 34 patients without DM who had CRD by etiology. The routine complete blood count, renal function, and number of CD34+ cells were determined for all of those involved in the study. The microalbumin/creatinine levels were measured, and glomerular filtration rates were calculated in all patients. The number of CD34+ cells was found to be significantly lower in the DM control group and DM-CRD group compared with the healthy group. No statistically significant difference was found between the NON-DM-CRD and the healthy control group. There was a moderate negative correlation between the ratio of microalbumin/creatinine and the number of CD34+ cells. A significant reduction in the number of CD34+ cells was shown in subjects with DM and ESRD caused by diabetic nephropathy.
Literatur
1.
Zurück zum Zitat Vaish M (2007) Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer 6:26PubMedCrossRef Vaish M (2007) Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer 6:26PubMedCrossRef
2.
Zurück zum Zitat Hatfield S, Ruohola-Baker H (2008) microRNA and stem cell function. Cell Tissue Res 331:57–66PubMedCrossRef Hatfield S, Ruohola-Baker H (2008) microRNA and stem cell function. Cell Tissue Res 331:57–66PubMedCrossRef
3.
Zurück zum Zitat Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM (2005) Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111(22):2981–2987PubMedCrossRef Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM (2005) Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111(22):2981–2987PubMedCrossRef
4.
Zurück zum Zitat Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348(7):593–600PubMedCrossRef Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348(7):593–600PubMedCrossRef
5.
Zurück zum Zitat Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ (2004) Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53(1):195–199PubMedCrossRef Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ (2004) Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53(1):195–199PubMedCrossRef
6.
Zurück zum Zitat Türk Nefroloji Derneği Yayınları (2009) Türkiye’de Nefroloji-Diyaliz ve Transplantasyon. Istanbul, Turkey Türk Nefroloji Derneği Yayınları (2009) Türkiye’de Nefroloji-Diyaliz ve Transplantasyon. Istanbul, Turkey
7.
Zurück zum Zitat Fadini GP, Miorin M, Facco M et al (2005) Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 45(9):1449–1457PubMedCrossRef Fadini GP, Miorin M, Facco M et al (2005) Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 45(9):1449–1457PubMedCrossRef
8.
Zurück zum Zitat Fadini GP, Sartore S, Albiero M et al (2006) Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 26(9):2140–2146PubMedCrossRef Fadini GP, Sartore S, Albiero M et al (2006) Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 26(9):2140–2146PubMedCrossRef
9.
Zurück zum Zitat Fadini GP, Pucci L, Vanacore R, Baesso I, Penno G et al (2007) Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia 50(10):2156–2163PubMedCrossRef Fadini GP, Pucci L, Vanacore R, Baesso I, Penno G et al (2007) Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia 50(10):2156–2163PubMedCrossRef
10.
Zurück zum Zitat Makino H, Okada S, Nagumo A, Sugisawa T et al (2009) Decreased circulating CD34 + cells are associated with progression of diabetic nephropathy. Diabet Med 26(2):171–173PubMedCrossRef Makino H, Okada S, Nagumo A, Sugisawa T et al (2009) Decreased circulating CD34 + cells are associated with progression of diabetic nephropathy. Diabet Med 26(2):171–173PubMedCrossRef
11.
Zurück zum Zitat Dessapt C, Karalliedde J, Dattani N, Atkar R et al (2010) Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care 33(4):875–877PubMedCrossRef Dessapt C, Karalliedde J, Dattani N, Atkar R et al (2010) Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care 33(4):875–877PubMedCrossRef
12.
Zurück zum Zitat Degroot K, Bahlmann FH, Sowa J et al (2004) Uremia causes endothelial progenitor cell deficiency. Kidney Int 66(2):641–646CrossRef Degroot K, Bahlmann FH, Sowa J et al (2004) Uremia causes endothelial progenitor cell deficiency. Kidney Int 66(2):641–646CrossRef
13.
Zurück zum Zitat Coppolino G, Bolignano D, Campo S, Loddo S, Teti D, Buemi M (2008) Circulating progenitor cells after cold pressor test in hypertensive and uremic patients. Hypertens Res 31(4):717–724PubMedCrossRef Coppolino G, Bolignano D, Campo S, Loddo S, Teti D, Buemi M (2008) Circulating progenitor cells after cold pressor test in hypertensive and uremic patients. Hypertens Res 31(4):717–724PubMedCrossRef
14.
Zurück zum Zitat Choi JH, Kim KL, Huh W, Kim B et al (2004) Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24(7):1246–1252PubMedCrossRef Choi JH, Kim KL, Huh W, Kim B et al (2004) Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24(7):1246–1252PubMedCrossRef
15.
Zurück zum Zitat Rodriguez-Ayala E, Yao Q, Holmen C, Lindholm B, Sumitran-Holgersson S, Stenvinkel P (2006) Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. Blood Purif 24(2):196–202PubMedCrossRef Rodriguez-Ayala E, Yao Q, Holmen C, Lindholm B, Sumitran-Holgersson S, Stenvinkel P (2006) Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. Blood Purif 24(2):196–202PubMedCrossRef
16.
Zurück zum Zitat Voltarelli JC, Couri CEB, Stracieri AB et al (2007) Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297(14):1568–1576PubMedCrossRef Voltarelli JC, Couri CEB, Stracieri AB et al (2007) Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297(14):1568–1576PubMedCrossRef
17.
Zurück zum Zitat Hong Z, Hao Ming T, Yang L et al (2009) Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin Med J 122(21):2573–2579 Hong Z, Hao Ming T, Yang L et al (2009) Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin Med J 122(21):2573–2579
18.
Zurück zum Zitat Chade AR, Xiangyang Z, Ronit L, James D, Simari RD et al (2009) Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 119(4):547–557PubMedCrossRef Chade AR, Xiangyang Z, Ronit L, James D, Simari RD et al (2009) Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 119(4):547–557PubMedCrossRef
Metadaten
Titel
The effect of diabetes mellitus and end-stage renal disease on the number of CD34+ cells in the blood
verfasst von
Cigdem Pala
Ilker Altun
Yavuz Koker
Fatih Kurnaz
Serdar Sivgin
Ismail Koçyiğit
Fatih Tanrıverdi
Leylagul Kaynar
Ferhan Elmali
Mustafa Cetin
Bülent Eser
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 9/2013
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1760-y

Weitere Artikel der Ausgabe 9/2013

Annals of Hematology 9/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.